While the expression of PD-L1 in tumor microenvironments has been evaluated as a predictive biomarker for immunotherapy in other solid tumors (i.e., melanoma, non-small cell lung cancer), the CheckMate 040 trial assessing Nivolumab as a second-line treatment for HCC did not find any differences in cancer response according to PD-L1 expression in tumor cells [19]. This evidence concerns the gene CD274 and cancer.